Drugs / AZD0156
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02588105 | Nov 2015 → Sep 2019 | cancer | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0156 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02588105 ↗ |
| Action | Inhibit | “AZD0156 is a potent and selective, bioavailable inhibitor of ataxia-telangiectasia mutated (ATM) protein” PMID 31534013 ↗ Sep 2019 |
| Route | Oral | “An oral formulation of AZD0156 will be used.” NCT02588105 ↗ |
| Target | ATM | “inhibitor of ataxia-telangiectasia mutated (ATM) protein” PMID 31534013 ↗ Sep 2019 |